Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
Homo sapiens protein kinase, DNA-activated, catalytic polypeptide (PRKDC), transcript variant 2
Synonyms:
DNA-PKcs; DNAPK; DNPK1; HYRC; HYRC1; p350; XRCC7
Immunogen
A phospho specific peptide corresponding to residues surrounding Serine 2056 of human DNA-PK/PRKDC was used as an immunogen. This antibody only detects DNA-PK/PRKDC phosphorylated at Serine 2056.
Buffer
Store at -20 °C. Buffer: Antibody buffer, sodium azide, glycerol, and BSA. Stable for 12 months from date of receipt.
DNA-activated serine/threonine protein kinase (DNA-PK) is a nuclear protein kinase that is involved in DNA nonhomologous end joining (NHEJ) required for double- strand brake repair and V(D)J recombination. DNA-PK is composed of a large catalytic subunit of ~470 kDa (DNA-PKcs) and a DNA binding heterodimer of approximately 70- and 80-kDa subunits called Ku. (1-2). Autophosphorylation of DNA-PK correlates with loss of protein kinase activity and dissociation of the DNA-PKcs-Ku complex. DNA-PK phosphorylates Hsp90, p53 and c-Jun (3-4).
Related Pathway
Cell cycle
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis on Jurkat cell lysates using anti-Phospho-DNA-PK/PRKDC (pS2056) RabMAb. Cells were either (A) untreated (B) treated with Alkaline Phosphatase.
